Ascendia

  MARKET NEWS

Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
One-carbon Therapeutics Signs Strategic Collaboration With Tempus to Advance Molecular Insights & Enable Precision Oncology Development of TH9619
Green Light for First-in-Human Trial of KMCAR T-cell Therapy in Multiple Myeloma
Vetter Des Plaines Facility is the German American Chamber of Commerce’s Investment of the Year
Neuland to Open Commercial Peptide Facility as part of Planned Phased Expansion
Lonza & Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO
Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections
Upperton Submits MHRA License Application for Annex 1 Sterile Manufacturing Facility Following APS Validation
Biologos Appoints New CEO, Celebrates 50 Years of Growth & Innovation
Medicus Pharma Reports Positive Phase 2 Topline Data Observing 73% Clinical Clearance & 40% Histological Clearance

  EXPERT CONTENT & RESOURCES

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

Portrait of Dr. Lara Zibners

The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve

Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.

Biocatalysis Without Barriers for Efficient Small Molecule Process Development

Biocatalysis Without Barriers for Efficient Small Molecule Process Development

As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.

Serán Bioscience presentation title slide: 'Right from the Start: Drug Product Design for Rapid Clinical Development' by Micah Tuttle

VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development

In this talk, Micah Tuttle demonstrates how intentional, forward-looking drug product design from day one can dramatically accelerate clinical development—eliminating the need for costly, time-consuming reformulations and bridging studies.

  FEATURED EDITORIAL

  COMPANY PROFILE

At Kindeva, we manufacture more tomorrows for patients worldwide. With best-in-class facilities and comprehensive CDMO services, we offer more than manufacturing—we deliver strategic value. Our global network of 10 manufacturing and R&D sites offer exceptional integrated knowledge and capabilities, including Annex 1-compliant state-of-the-art aseptic fill finish capacity and next-generation sustainable inhalation propellant technology. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 25 – Excipients
April 1 – Inhalation Drug Delivery